How To Organize A Biotechnology Conference In Lille

Transcription

1 December 2 & Lille FRANCE A 360 approach to build life sciences partnerships PROGRAM Organized by In cooperation with

2 Welcome to BioFIT 2014 Edito For the third time, BioFIT offers international actors in the life sciences a meeting place between public and private stakeholders and keeps fostering the emergence of new and innovative projects and products. The desire to join forces has brought actors from various sectors (pharma, biotech, medtech, IVD, animal health, technology transfer, licensing and IP professionals, academia and investors...) to discuss partnerships and bring the most relevant public and private audience to Lille on December 2 nd and 3 rd. On the agenda: partnering activities with pre-screened one-to-one meetings a conference program dealing with collaborative research, new funding sources and new approaches in technology transfer, a presenting technologies session offering the possibility to present key technologies, licensing opportunities and product development. This edition is the event not to be missed as it will gather over attendees from 25 countries, including leading companies and professionals from pharma, biotech, medtech, IVD but also technology transfer, licensing and IP professionals, academia and investors. Thanks to the quality and diversity of its participants, BioFIT looks certain to generate this year again, excellent collaborating opportunities. With this vote of confidence received from its attendees, the event has been taken to the next level and we are proud to announce that BioFIT will become a yearly event. Its 4 th edition will be held in Strasbourg on December 1 st & 2 nd, 2015! Mark it in your agendas and join us! We wish you a fruitful and enjoyable two-day event full of meetings and partnership opportunities and hope to see you again next year! Etienne VERVAECKE, General Commissioner of BioFIT 2014 and Eurasanté General Manager organizers Eurasanté is the economic development agency dedicated to Health, Nutrition and Biotechnology in the Nord-Pas de Calais region. Eurasanté offers since 1996 a complete range of services allowing to define, strengthen, finance and launch every development project on the health and nutrition markets. Nutrition Health Longevity (NHL) Cluster is a dynamic network focusing on today s main health issues, at the crossroads of Nutrition, Biotechnology, and Health. In the Health sector, NHL focuses on developing preventive, diagnostic, and therapeutic solutions applicable to cardiovascular and metabolic conditions, neurodegenerative diseases and Inflammatory Bowel Diseases (IBD). Its projects in the Food sector aim at protecting health and well-being through a safe, healthy, and sustainable diet. In cooperation with Lille - Biofit // 2

3 summary Editorial 2 BIOFIT Agenda 4/5 STEERING COMMITTEE 6 floor plan/exhibitors list 8/9 PARTNERING ACTIVITIES 11 Plenary session 14 December 2 nd 15 BIOPARTY 18 December 3 rd 19 Posters & presentations 25 OUR MISSION: THERAPEUTIC INNOVATION GENFIT (Euronext Paris:GNFT) is a biopharmaceutical company at the forefront of developing therapeutic and diagnostic solutions in fields of high medical need due to a lack of suitable treatment and an increasing number of patients worldwide.! GENFIT s R&D efforts are focused on bringing new medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases, that affect the liver (such as NASH - Nonalcoholic steatohepatitis) or the bowel (such as inflammatory bowel disease).! GFT505 is GENFIT s lead pipeline product for the treatment of NASH, a major recognized unmet medical need.!! Connect together: GENFIT Headquarters - Parc Eurasanté 885, Avenue Eugène Avinée Loos France +33 (0) !

4 AGENDA DAY ONE december 2 nd CONFERENCES PARTNERING hosted events am Registration and Exhibition opening/ Welcome coffee am am coffee break pm pm lunch pm RUBENS ROOM Who will be funding the maturation phase in the future? pm coffee break Big consortia: how do they work and what are their outcomes? Pasteur AMPHITHEATRE FAIDHERBE ROOM RUBENS ROOM One-to-one meetings PLENARY SESSION Accessing innovation: how to build long term partnerships? RUBENS ROOM New models for bridging the gap from research to market One-to-one meetings PLENARY SESSION Pasteur Amphitheatre Animal Health: a key actor in tomorrow s innovations? Technologies & Services Presentations Full program p.25 In partnership with European Genomic Institute for Diabetes Meta-inflammation in diabetes and its complications 8:30 am: Registration / Welcome coffee 9:00 am: Role of gut microbiota in the European Genomic Institute for Diabetes pathogenesis of diabetes 9:45 am: Role of innate and adaptive immunity in atherosclerosis 10:30 am: Coffee break 11:00 am: Islet inflammation in type 2 diabetes 11:45 am: Poster session 12:30 pm: Lunch 2:00 pm: The impact of sleep loss and circadian misalignment on metabolism 2:45 pm: Metabolic control of nash 3:30 am: Coffee break 4:00 pm: Brown adipose tissue and skeletal muscle mitochondrial function as targets for the treatment of type 2 diabetes: focus on human intervention studies 4:45 pm: Best poster award 5:00 pm: Conclusions EGID Symposium Eurotop Auditorium pm Looking ahead: can big data hold the key to breakthrough treatments? pm bioparty Lille - Biofit // 4

5 AGENDA CONFERENCES PARTNERING hosted events am Registration and Exhibition opening/ Welcome coffee am l Driving innovation in Europe: using Horizon 2020 program am coffee break pm pm lunch Emerge & happen: creative solutions for difficult problems in dealmaking pm Make it work and last: how to best apply strategic alliance management pm coffee break pm FAIDHERBE ROOM RUBENS ROOM RUBENS ROOM RUBENS ROOM Scouting innovation: academia push and industry pull RUBENS ROOM Biotech meets Medtech: a future perspective FAIDHERBE ROOM l The valuation process: do all stakeholders use the same criteria? FAIDHERBE ROOM New practices from the VC industry in sourcing innovation FAIDHERBE ROOM l The road less traveled: new approaches to finance early stage innovation One-to-one meetings One-to-one meetings Artois Room 8:30 am: Welcome coffee 9:15 am: Open Board of Directors 11:00 am - 12:30 pm: Speeches and exchanges 2:00 pm: Meeting: Working Group Major Accounts 4:00 pm: Outsourcing: the future of the industry Eurotop Auditorium 8:30 am: Welcome coffee 9:00 am - 10:30 am: Breakthroughs & innovations in the field of diabetes 11:00 am - 12:30 pm: What do you expect as a good level of maturity of research finding? Too early stage for me guy!! 12:30 pm: Lunch 2:00 pm - 3:30 pm: Is stratified/personalized/precision medicine one of the paradigm on which we could ground our collective efforts for research in diabetes? 4:00 pm - 5:30 pm: Do we need a European joint diabetes research agenda? who should contribute to it? what should be the goals of this joint research agenda? track 1 Emerge, last and deliver: best practices in collaborative research track 2 Early stage innovation: new routes to funding sources l track 3 Creative solutions for transferring innovation to market: TTO s and industry s new approaches DAY two december 3 rd Lille - Biofit // 5

6 steering committee BioFIT 2014 is honored to receive the support of a prestigious Steering Committee composed of 19 renowned international experts in their fields, coming from different sectors: academia, industry, clusters, service providers The BioFIT 2014 Steering Committee ensures the relevance of the conference program and contributes to the choice of the speakers. Industries Associations, Clusters, Investors Academia, TTOs Zeina ANTOUN, Clinical Research Director, GSK - GlaxoSmithKline (FR) Maria BOBADILLA, Senior Director, Extending Innovation Network, Roche (CH) Sami CHTOUROU, Director of technology platforms and innovation, LFB (FR) Maria M. FLOCCO, Senior Director, Head Strategic Research Partnerships Europe, Pfizer (FR) Guy HELIN, CEO, Syngulon (BE) Tomas LANDH, Director, Strategy & Innovation Sourcing, Diabetes Research Unit, Novo Nordisk (DK) Stephan LENSKY, Vice President Strategic Transaction & Alliances, BOEHRINGER INGELHEIM (DE) Frédéric SCAEROU, Director, Scientific Affairs Oncology, Ipsen Innovation (FR) Mohammed CHARKI, Research & Development Partnerships Director, Global Project Leader Online Open Innovation, Sanofi (FR) Richard BERGSTROM, Director General, EFPIA - European Federation of Pharmaceutical Industries and Associations (BE) Claude-Alain CUDENNEC, General Director, AFSSI - Association Française des Sociétés de Services et d Innovation (FR) Isabelle DIAZ, Research & Biotechnology Director, LEEM / General Secretary, ARIIS - Alliance pour la Recherche et l Innovation des Industries de Santé (FR) Marco FIORINI, General Secretary, Aviesan - French National Alliance for Life Sciences and Health (FR) Gunilla EKSTROM, Vice President Operations, Karolinska Development (SE) Titta ROSVALL-PUPLETT, Executive Director, EBE - European Biopharmaceutical Enterprises (BE) Anne ROY, Journalist, AEF Specialized news agency (FR) Emilie ROYERE, Director, Eurobiomed (FR) Hervé ANSANAY, Business Developer, SATT Nord (FR) Ivan BAINES, Chief Operating Officer, Max Planck Institute of Molecular Cell Biology and Genetics (DE) Garold BREIT, CEO, Breit Ideas (USA) Nicolas CARBONI, President, SATT Conectus Alsace (FR) Jean-Luc CHAGNAUD, Healthcare Business Development Manager & IP Manager, Aquitaine Science Transfert (FR) Esther LANGE, Industry Liason Manager, Ascenion (DE) BioFIT for me is one of the best places where you can meet academics, big pharma and biotech. It s really a unique opportunity to meet them all in one place. Guy HELIN, CEO, Syngulon Lille - Biofit // 6

7 80% of our development projects are biologics 9 high-potential projects are in late-stage* 4.8 bn of investment in R&D in 2013 Palani Mohan Dean, Australia, with multiple sclerosis EXPLORING THE BOUNDARIES OF MEDICAL INNOVATION Sanofi has created an open innovation model, based on solid collaborations with its partners and the scientific community. With this new R&D approach, Sanofi can meet its main challenges: accelerating the transformation of scientific innovation into targeted therapeutic solutions for patients and developing new biologic entities. *As of february 6, 2014

8 European Genomic Institute for Diabetes European Genomic Institute for Diabetes floor plan FLANDRES HALL level 8 exhibitors list Internet Terminals Coffee Break Partnering Desk 1 Poster Area Breakfast, Coffee Breaks A C B Partnering Desk 1 Bar Poster Area Coffee Break D Conferences Rooms (Rubens, Faidherbe, Goya) Preview Room (Rembrandt) Access to Level 11 Partnering - Lunch Area E 21 Access to Pasteur Amphitheatre Coffee Break Access to Welcome Desk - Eurotop Auditorium AFSSI (French Association of Outsourcing and Innovative Companies in the field of Life Sciences) ADVANCED BIODESIGN BIOSIMS TECHNOLOGIES CELL&CO BIOREPOSITORY CILCARE EVEDRUG PHYLOGENE PHYTOSAFE POPSI CUBE RD-BIOTECH ROOWIN EGID (European Genomic Institute for D Diabetes) ILLUMINA RAMERY TRACE ARCHITECTES EURASANTE & NHL CLUSTER C APTEEUS EATCELL BIOTECH E-ZYVEC KIBIOS MACOPHARMA OCR SMARTMABS VAXINANO X PROCHEM Réseau SATT (Tech Transfer Accelerator Network) B SIMV (French Association of Animal Health Industry) E 4P-PHARMA 6 ADMESCOPE 20 AMYLGEN 2 ATLANPOLE BIOTHERAPIES 10 BACCINEX 11 CITOXLAB 1 CYANAGEN 18 ERDYN 17 EUROPEAN COMMISSION 19 HAZGO 9 IP PRAGMATICS 21 MEDICEN PARIS REGION 8 MERCODIA 15 MITA - Agency for Science, Innovation 4 and Technology NORGINE 12 ORIGINAL PROCESS 22 PIERRE FABRE CDMO 3 PRAXIS PHARMACEUTICAL 5 RWS GROUP 14 SCREENCELL 13 SOLADIS 7 STRATICELL 16 A Lille - Biofit // 8

9 floor plan JEANNE DE FLANDRE HALL level 11 Access to Level 8, Flandres Hall Catering Partnering Booths 1 Poster Area Partnering Desk Catering Poster Area Partnering Desk 2 Partnering Booths 1-44 Sponsor Meeting Rooms Poster Area Catering Poster Area Internet Terminals Luncheon AP instit 210x148_Mise en page 1 20/11/14 15:57 Page1 AUJOURD HUI ET DEMAIN conception : VOUS POUVEZ COMPTER SUR LE GROUPE LFB Groupe biopharmaceutique français, le LFB est présent dans les domaines de l immunologie, de l hémostase et des soins intensifs avec une large gamme de médicaments dérivés du plasma qui traitent chaque année plus de patients atteints de pathologies graves et parfois très rares. Afin de faire progresser la prise en charge de certaines pathologies très graves et améliorer également l'accessibilité de certains traitements, le LFB développe des programmes dans les biotechnologies avec deux axes de développement majeurs : les anticorps monoclonaux et les protéines recombinantes par transgénèse. Le LFB s'engage pour relever les défis thérapeutiques et technologiques des traitements de demain.

10 Meet at BioFIT 2014 through Please collect a print out of your partnering schedule at the partnering desk which is located in the exhibition hall and opposite the partnering booths Network with 26,000 dealmakers Gain key insights and knowledge Promote your company, products or ideas YOU Screen 12,000 companies for partnering fit Engage in expert groups Monitor Leverage the social web partnering360 is an online network of life science dealmakers, providing

11 PARTNERING ACTIVITIES who will you meet Ascenion, AstraZeneca, Bayer, Boehringer Ingelheim, Evotec, Pfizer, Roche, Eli Lilly, Sanofi, GSK, Takeda, Max Planck Institute, Karolinska Institute, Provendis, University of Oxford, Leiden University, King s College London, ISIS Innovation, Pasteur Institute, Institute Curie, Inserm Transfert, Karolinska Development, Kurma Partners, Index Ventures, GIMV, Novo Seeds, Imperial Innovations and many others 43% Pharmas, Biotechs, Medtechs 28% Investors, Clusters, Services 29% Academics, TTO BioFIT s partnering platform is powered by renowned software, which has already facilitated over 40,000 one-to-one meetings at events worldwide in the past 18 months and is the most widely used partnering platform in the life sciences industry. 25 represented countries Germany Spain Czech Republic Ireland France Italy Belgium Poland Netherlands Switzerland Portugal Japan Finland Israel Denmark Canada Lithuania Sweden Hungary Norway United States United Kingdom Luxembourg Austria Lille - Biofit // 11

12 novo nordisk Partnering for innovation IN PROTEIN-BASED THERAPEUTICS AND TECHNOLOGIES Novo Nordisk is a world leader in diabetes care and we have a leading position within haemostasis management and growth hormone therapy. We have refined our protein competencies since 1923, and have developed world class expertise in driving proteins from molecule to market. We continuously look for new partnerships. DIABETES Novel proteins or peptides affecting any aspect of diabetes; Novel treatments for obesity, diabetes complications and T1D. HAEMOPHILIA Novel non-replacement therapies that improve haemostasis. TECHNOLOGY Technologies for expressing, modifying or producing proteins and peptides; Formulation and drug delivery technologies for proteins and peptides. For more information and to contact us visit Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 40,700 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com.

13 Your innovation partner At the crossroads of Nutrition, Biotechnology and Health is co-organised by NHL Cluster

14 december 2 nd PLENARY SESSION Accessing innovation: how to build long term partnerships? Pharma s interest for early stage technologies is no longer news in the life sciences industry. In their quest to accessing knowledge, pharma and large biotech get more and more involved in early stage research, either by supporting big consortia or building collaborative research partnerships directly with academia. However, what do we know about the success of such partnerships and big consortia? Have they really worked and what were the outcomes? am 12:30 pm Pasteur AMPHITHEATRE Chairman John HODGSON, Data Editor, Scripp Intelligence (UK) Mike MARTIN, Senior Director, Search & Evaluation, Takeda (USA) Wen Hwa LEE, Strategic Alliances Manager, University of Oxford, Nuffield Department of Medicine (UK) Werner LANTHALER, CEO, Evotec (DE) Schwarz Holger, External Innovation, Merck Serono (DE)

15 december 2 nd BioFIT for me is the place to be if you want to learn from others in tech transfer from academia to pharma and develop business. Nicolas CARBONI, President, SATT Conectus Alsace 9.00 am 10:30 am RUBENS ROOM Chairman Hugh LAVERTY, Senior Scientific Project Manager, IMI - Innovative Medicines Initiative (BE) Big consortia: how do they work and what are their outcomes? Many companies and research institutes are getting more and more involved in consortia of different sizes in order to work together around specific questions they are all looking to find an answer to. Of course their organization can be very different depending on the number of partners involved and the questions addressed. But how can their outcomes be evaluated, knowing that what comes out is non-tangible knowledge which itself is later used in other R&D processes in order to obtain real results? Moreover, what type of guidance is necessary in order to make them work and obtain successful outcomes? Bernd STOWASSER, Head of Public Private Partnerships - External Innovation & Science Policy, Sanofi (DE) Jacky VONDERSCHER, President, Enyo Pharma (FR) Bruno FRANCOIS, Clinical Lead COMBACTE Consortium, CHU Limoges/Inserm (FR) 2.00 pm 3:30 pm Rubens Room Chairman Garold BREIT, Owner, Breit Ideas (USA) New models for bridging the gap from research to market Even though there are many collaborations put in place between pharma and academia, the gap from academic discovery to market still exists. In this context, we are witnessing the emergence of new initiatives like pharma-driven innovation centers, incubators and consortia. Their purpose is to help advance drug discovery projects by accelerating the process of innovation, but what impact will they have on the life sciences ecosystem, including the pharma-biotech relationships? Duncan HOLMES, European Head, Discovery Partnerships with Academia, GSK (UK) Jeffrey ULMER, Global Head of External R&D, Novartis Vaccines (USA) Stefaan ALLEMEERSCH, Director Business Development, Centre for Drug Design and Discovery (CD3 Leuven) (BE) Christian TIDONA, Founder & Managing Director, Biomed X Innovation Center (DE) Odile PIOT-GROSJEAN, Strasbourg R&D Site Director, SANOFI (FR) Lille Biofit 15

16 GSK, A KEY PLAYER IN R&D GlaxoSmithKline is a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world, helping them to do more, feel better and live longer. We have three primary areas of business in pharmaceuticals, vaccines and consumer healthcare. Our commercial success depends on creating innovative new products and making these accessible to as many people as possible. By achieving this, we will be able to grow our business and provide benefits to patients, consumers, society, our employees and our shareholders. Our headquarters are based in the UK, and we have a wide geographical reach. We have offices in more than 115 countries, major research centres in the UK, USA, Spain, Belgium and China and an extensive manufacturing network with 87 sites globally. Research is vitally important to the success of our business, and we spent just under 4 billion in 2012 in our search to develop new medicines, vaccines and innovating consumer products. We are one of the few healthcare companies researching medicines and vaccines for the World Health Organisation s three priority diseases - HIV/AIDS, tuberculosis and malaria. As a science-led global healthcare company we have the opportunity to improve the health and well-being of millions of people around the world. Through investment in R&D and infrastructure, and through collaboration with other organisms, we are innovating to address currently unmet health needs. We are improving access to our products, irrespective of where people live or their ability to pay, and we are working to control or eliminate diseases affecting the world s most vulnerable people. FR/GSKI/0011/13 12 septembre 2013 Laboratoire GlaxoSmithKline

17 december 2 nd 2.00 pm 3:30 pm Faidherbe Room Chairman Nicolas CARBONI, President, SATT Conectus Alsace (FR) Who will be funding the maturation phase in the future? In a difficult economic climate, in which venture companies prefer to invest in lower risk or mature enterprises, finding financial resources for project maturation seems to get ever more complicated. To whom do TTOs and academic laboratories turn when looking for funding at this stage and which are the best strategies to spin-off the technology so as to ensure its success? Rémi DROLLER, Managing Partner, Kurma Partners (FR) Tony HICKSON, Managing Director, Technology Transfer, Imperial Innovations (UK) Manfred HORST, Director, Scientific Liaison France, Ge, Eastern EU Licensing & External Research EU, Merck Sharp & Dohme (FR) Matthieu COUTET, VP operation & Business Development, aavlife (FR) BioFIT is covering key aspects of getting better at working with external partners, identifying them and finding alternative sources of funding. Frédéric SCAEROU, Director, Scientific Affairs Oncology, Ipsen fnd out more today

18 december 2 nd I believe that, in this post crisis era, the importance of partnering cannot be overstated. BioFIT has been structured to meet the needs of the industry and academy and research institutions. Moreover, Lille affords a convenient user-friendly environment in which to meet and conduct business. Garold Breit, CEO, Breit Ideas (USA) 4.00 pm 5:30 pm RUBENS ROOM Looking ahead: can big data hold the key to breakthrough treatments? In today s healthcare system, we are able to collect large sets of data at multiple levels. However, how can they be transformed into knowledge? This particular aspect is being addressed in large consortia organized by big pharmas together with biotech and IT companies. Let s find out how they are working and whether they can help get concrete outcomes in terms of use of this data, of handling it and hear about some successful outcomes. Chairperson Nora BENHABILLES, Manager Program, Health sector, CEA (FR) INVITATION DECEMBER 2 nd :00 pm TRIPOSTAL LILLE - FRANCE A shuttle service is provided to pick you up at Lille Grand Palais and take you to the Tripostal Times of departure from Lille Grand Palais 6.30 pm & 6.40 pm 7.00 pm & 7.10 pm Kai SIMONS, Research Group Leader and Director Emeritus, Max Planck Institute of Cell Biology and Genetics (DE) Philippe SANSEAU, Head Computational Biology, GSK (UK) Jesper TEGNER, Strategic Professor of Computational Medicine Director, Unit of Computational Medicine, Karolinska Institute (SE) Hans CONSTANDT, CEO, Ontoforce (DE) Nathalie JOURDAN, CEO, Bioptimize (FR) Exhibition Networking Cocktail Lille - Biofit // 18

19 december 3 rd 9.00 am 10:30 am Rubens Room Chairman Garold BREIT, Owner, Breit Ideas (USA) Biotech meets Medtech: a future perspective At first glance, there is a clear dividing line between medical technology and biotechnology. In actual fact, the two areas are not always easy to separate and the boundaries are becoming increasingly blurred. One thing is certain the will to join forces is there. But how do these collaborations work in reality? Let s hear from our panelists examples of cooperation between biotech and medtech and how they perceive the future of this sector. Eric HALIOUA, CEO, Promethera (BE) Magnus BJÖRSNE, Executive Director, AstraZeneca BioVenture Hub (SE) Manfred KAUER, Senior Deputy Director, BioRegio STERN (DE)

20 december 3 rd 9.00 am 10:30 am Faidherbe Room Chairman Cormac SHERIDAN, journalist, Bioworld (IRELAND) l Driving innovation in Europe: using Horizon 2020 program In order to speed up innovation, it is obvious that research alone is not enough. It also needs to be put into use. Therefore, the EU began funding not only the research activities, but also the commercialization of these results. Let s discuss in this session, what Horizon 2020 has to offer to the technology transfer community in life sciences and how to take advantage of these opportunities to be more efficient. Aletta DEBERNARDI, Senior Advisor Research Funding, Leiden University, LURIS (NL) Hugh LAVERTY, Senior Scientific Project Manager, IMI - Innovative Medicines Initiative (BE) Philippe CUPERS, DG Research and Innovation, Head of Neurosciences Sector, European Commission (BE) Philippe VERWAERDE, CEO, Alzprotect (FR) am 12:30 pm RUBENS ROOM Chairman Mark Bradley WILSON, PARTNER, Norton Rose Fulbright (USA) Emerge & happen: creative solutions to difficult problems in dealmaking That things can go wrong in negotiations and partnership is not surprising. However, when you encounter these problems, sometimes creative solutions are needed in order to finally create a mutually beneficial partnership. During this interactive session, the panelists will discuss the common and not so comment pitfalls in partnering and negotiations, as well as share their experience on the different stages of negotiations, the difficulties they ran into and the solutions they found. Stephan LENSKY, Vice President Strategic Transaction & Alliances, Boehringer Ingelheim (DE) Jürgen WALKENHORST, Head of Life Sciences, Provendis GmbH (DE) Pascale REDIG, Member of ASTP-Proton Professional Development Committee, NL Senior Sourcing Manager of Global Pharma R&D, Janssen Pharmaceutica NV (BE) am 12:30 pm FAIDHERBE ROOM Chairman l Ivan C. BAINES, Chief Operating Officer, Max Planck Institute of Molecular Cell Biology and Genetics (DE) The valuation process: do all stakeholders use the same criteria? Everyone knows putting a value on a technology or know-how is a challenging process. And if the value is not correctly measured, it could get a wrong start for the project or create difficulties in transferring the technology. So let s try to find out from our panel of experts how value is measured in the life sciences field. Do all the stakeholders (TTOs, VCs, pharma and biotech) use the same criteria? Ed SALTZMAN, President, Defined Health (USA) Daniel BACH, Managing Partner, Aravis (CH) Mohammed CHARKI, Research &Development Partnerships Director, Sanofi (FR) Lille - Biofit // 20

21 december 3 rd 2.00 pm 3:30 pm RUBENS ROOM Chairman Mark Bradley WILSON, PARTNER, Norton Rose Fulbright (USA) Make it work and last: how to best apply strategic alliance management The deal signature is just the beginning of a long road to travel for putting in place a successful partnership. The alliance management is an important piece of the puzzle and if well implemented and understood by both parties, it becomes an effective and invaluable tool in the management of the deal. Let s discuss how to set it correctly on paper and how to identify the right key licensing terms to the deal and how to manage the partnership in an efficient and rewarding way for both parties. Stephan LENSKY, Vice President Strategic Transaction & Alliances, Boehringer Ingelheim (DE) Jürgen WALKENHORST, Head of Life Sciences, Provendis GmbH (DE) Pascale REDIG, Member of ASTP-Proton Professional Development Committee, NL Senior Sourcing Manager of Global Pharma R&D, Janssen Pharmaceutica NV (BE) history_148x210_4c.qxd:biofit :56 Uhr Seite 1 BioFIT is a European independent event and it fits very well into fostering the targets that we have in identifying innovation. Tomas LANDH, Director, Strategy & Innovation Sourcing, Diabetes Research Unit, Novo Nordisk Value through Innovation The chemist and Nobel Prize winner Professor Heinrich Wieland (right) was in charge of setting up the company s first scientific department in the 1920s. Research for health calls for endurance. The best thing is to make an early start. For Boehringer Ingelheim, success as a pharmaceutical company for more than 129 years has been synonymous with introducing innovative medications. In researching and developing new therapies and dosage forms the company invested around 2.7 billion in 2012 alone. This investment in the future has a long tradition. So it s no coincidence that Boehringer Ingelheim is one of the 20 most successful companies in pharmacetuicals worldwide. Research is our driving force. More than 47,400 employees around the globe, of whom some 13,900 are in Germany, are working to improve the prospects for healthier lives.

22 december 3 rd 2.00 pm 3:30 pm FAIDHERBE ROOM Chairman Stephane Mottola, Director of International Development, FIST (FR) New practices from the VC industry in sourcing innovation The traditional VC industry invests in young start-ups once they evaluate the project and the potential outcomes. However, recently they have started looking more into academia and approaching research projects in order to detect innovation as early as possible, support it and help it get mature. Has this trend generalized in the industry so as to speak of a shifting environment? How are pharma and biotech seeing this and is academia interested in the bargain? Giovanni Mariggi, Associate, Index Ventures (CH) Magnus BJÖRSNE, Executive Director, AstraZeneca BioVenture Hub (SE) Christophe VAN VAECK, Senior Investment Manager Life Sciences, GIMV (BE) Nanna LÜNEBORG, Investment Director, Novo Seeds (DK) 4.00 pm 5:30 pm Faidherbe Room Chairman Georg KÄÄB, Cluster Manager Bavarian Biotech Cluster, Bio-M Corporate Communications, BioM Biotech Cluster Development Development GmbH (DE) Scouting innovation: academia push and industry pull Academia wants to push out knowledge and innovation on the one hand and the industry is looking to pull it in and bring it to market on the other hand. However simple this might seem, when putting it into practice there are many challenges to overcome. Let s find out which are the new models that pharma and biotech are using in scouting innovation and how are TTOs better packaging the offer in order to find more matches with the demand? Adam STOTEN, Deputy Head of Technology Transfer, ISIS Innovation (UK) Raj MEHTA, Business Development Executive, Cancer Research Technology (UK) Jane Atkins Director, Global Licensing & Business Development (CH) Lille - Biofit // 22

23 Dan Tentler / Getty Images Caroline, still as style-conscious as ever... and Ipsen played an important part in keeping it that way. For Caroline, who suffers from a debilitating disease, challenging her friends to a quad bike race is priceless. Each year, Ipsen invests 20% of its sales in R&D to further its expertise in three specialty care areas: urology-oncology, endocrinology and neurology. The company also has a significant presence in primary care. In more than 100 countries, Ipsen employees devote their energy and skills to developing innovative therapeutic solutions for debilitating diseases and improving the quality of life of patients.

24 210x148_ProgHeft_Kapsel_e.indd :00 december 3 rd 4.00 pm 5:30 pm Rubens Room l The road less traveled: new approaches to finance early stage innovation Chairman Claire Skentelbery, Secretary General, European Biotechnology Network (BE) Many experts believe the era of the traditional venture-backed financing model to fund drug development has passed. If this is true, what other models can companies explore for driving innovation? In this session we will discuss some of the alternative paths to funding drug discovery and development, including new collaborative and business approaches, in a challenging economic environment Axel KALINOWSKI, Manager Continental Europe, London Stock Exchange (UK) Souleymane Galadima, Director of Development, WiSEED (FR) Lucia Robert, Director, MATWIN (FR) Condensed innovation 10 years of research in just one cubic centimetre. Our innovations help millions of people by alleviating their suffering and improving their quality of life. We give them hope.

25 Posters & presentations Goya ROOM December 2 nd from 2:00 pm 5:45 pm Come and listen to 10 min pitches of innovative technologies, products and services ABUNDNZ Ultrasensitive assay for bioanalytical studies with innovative medicines CAPSULAE Microencapsulation as a solution for therapeutic applications CYANAGEN Novel fluorescent IR-marker for monitoring the kidney function VITAMFERO VitamFero : a novel generation of veterinary live attenuated prophylactic treatments DELPHI GENETICS The Staby technology: No antibiotics and higher yields in recombinant proteins, pdna productions and antibody development IMSTAR Innovative Image Cytometry Solutions for biomarkers identification and validation in research and cyto-pathology INMOTE MEDTECH Inmote MedTech: Easy, secure and consistent documentation in woundcare JAGIELLONIAN UNI Novel antiviral agents against coronaviruses OCR OCR The OneHealth Company QUINTEN Quinten: Expert in strategic data leveraging 2BIND Fast and quantitative analysis of molecular interactions using the MicroScale Thermophoresis (MST) 3M 3M Emphaze aex hybrid purifier: purification to the next level 4P PHARMA Translating science to product: General methodolodgy for addressing technological and financial Challenges 2:00 pm 2:15 pm 2:30 pm 2:45 pm 3:00 pm 3:15 pm 4:00 pm 4:15 pm 4:30 pm 4:45 pm 5:00 pm 5:15 pm 5:30 pm Discover more technologies and services at the Poster Area - Espace Jeanne de Flandre - Level 8 4P PHARMA, AMYLGEN, KALLIS- TEM, OCR, QUANTACELL, QUIN- TEN, VOXCAN, 3M, CAPSULAE, CATALENT, CYANAGEN, ORIGINAL PROCESS, VITAMFERO, 2BIND, ABUNDNZ, INRA, SOLADIS, CAPI- TOL EUROPE, DELPHI GENETICS, IMSTAR, INMOTE MEDTECH, JA- GIELLONIAN UNI, SEPPIC, SUSSEX UNI The Poster & Presentation session is organized in partnership with the LEEM Lille - Biofit // 25

26

27 They support us Sponsors Gold silver bronze contributing Farbe/colour: PANTONE 288 CV tium de sor on orisation al hémat ique T V C Supporters CMYK Blue: 100/15/0/35 Orange: 0/75/90/0 Biotechnologie-Industrie-Organisation Deutschland e. V. FEBiotec F e d e r a c i ó n E s p a ñ o l a d e B i o t e c n ó l o g o s media supporters institutional partners Event Management: Conference Program: Registration & Sponsorship: Event Venue Marion SIGIER +33 (0) msigier@eurasante.com Ramona PIRV +33 (0) rpirv@eurasante.com Margaux SATOLA +33 (0) msatola@eurasante.com Lille Grand Palais 1 bd des Cités Unies F Lille-Euralille FRANCE

28 SAVE THE DATE NEW LOCATION th EDITION Printed on recycled paper Photos credits : Sven Hoppe/Fotolia - Eurasante Want to learn all about BioFIT 2015? Register online! Organized by Supported by